News

Sticky Post
Company pursuing an advanced small molecule MOS-118 (formerly known as AVE0118) discovered by Sanofi. Experienced team with strong background in Metabolic Diseases and Obstructive Sleep Apnea. Seed financing led by Forty51 Ventures. Basel, Switzerland, July 13, 2022 /PRNewswire/ — Mosanna Therapeutics AG, a Swiss Biotech company today announced that it has secured seed financing led by Forty51 Ventures to pursue the development of AVE0118 which will be referred to as MOS-118 going forward, a small...
Read More